Bristol-Myers Squibb Company (BMY)
US FDA approves Bristol Myers' schizophrenia drug
The U.S. health regulator approved Bristol Myers Squibb's schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects, the company said.
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
The Food and Drug Administration approved Bristol Myers Squibb's highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. The company expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October.
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
2seventy bio, Inc TSVT and its partner Bristol Myers Squibb & Co BMY, will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
Bristol Myers Squibb (BMY) closed at $49.49 in the latest trading session, marking a -1% move from the prior day.
3 Wide Moat Stocks to Buy for an Economic Slowdown
#Morningstar #MicrosoftStock #StockInvesting These undervalued stocks have defensive qualities that make them attractive in today's market. 00:00 Introduction 00:43 Bristol Myers Squibb BMY 01:22 Campbell Soup CPB 02:11 Microsoft MSFT I'm Susan Dziubinski with Morningstar.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Bristol Myers Squibb and Gilead Sciences are longtime healthcare leaders. Both have the innovative abilities needed to continue developing new drugs.
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
Bristol Myers Squibb Dividend Yield Pushes Past 5%
In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $47.55 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
Bristol Myers Squibb: Momentum Still Promising Through H2 2024, Turnaround Likely Prolonged
BMY's rally from the July 2024 bottom is well deserved, as the market rotated from high growth to high dividend-yielding sectors. This is significantly aided by the pharmaceutical company's robust FQ2'24 performance and raised FY2024 guidance. Readers must not forget the numerous tailwinds from H2'24 to 2026 as BMY increasingly monetizes its in-house/acquired pipelines.
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its dividend payout by 46% over the past five years.
Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025
Bristol-Myers Squibb delivered a significant earnings beat in Q2, driving shares up 20% since spring and boosting sector performance. Despite concerns about long-term EPS, strong Q2 results and improved guidance support a buy rating, with a valuation target near $76. BMY's technical chart shows bullish signals, including a potential golden cross and improved RSI momentum, indicating a favorable trend.
